Name | AZD-8529 mesylate |
Description | AZD-8529 mesylate is a highly selective, and orally bioavailable positive allosteric modulator of mGluR2 (EC50: 285 nM). It shows no positive allosteric modulator responses at 20-25 M on the mGluR1, 3, 4, 5, 6, 7, and 8 subtypes. |
In vitro | AZD-8529 potentiates the effects of glutamate at mGluR2 (EC50: 195 nM). It does not elicit antagonist responses on mGluRs at 25 μM. |
In vivo | AZD-8529 (30 mg/kg; i.p.) decreases the increased extracellular dopamine induced by nicotine in accumbens shell of freely-moving rats. AZD-8529 (0.3-mg/kg, i.m.) reduces nicotine priming-induced and cue-induced reinstatement in squirrel monkeys. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 41.67 mg/mL (71.40 mM), Sonication is recommended.
|
Keywords | Inhibitor | addiction | AZD-8529 | AZD 8529 | AZD8529 | treatment | AZD8529 Mesylate | inhibit | receptor | mGluR | AZD-8529 Mesylate | Metabotropic glutamate receptors | mGluR2 | AZD8529 mesylate | nicotine | AZD 8529 mesylate | AZD 8529 Mesylate |
Inhibitors Related | IDRA-21 | Topiramate | Decanoic Acid | Urethane | L-Cysteic acid monohydrate | Evans blue | L-Glutamine | Direct Blue 1 | L-Glutamic acid monosodium salt | Piracetam | O-Phospho-L-serine | Memantine hydrochloride |
Related Compound Libraries | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Neurotransmitter Receptor Compound Library | Drug Repurposing Compound Library | NO PAINS Compound Library | Orally Active Compound Library | Clinical Compound Library | Bioactive Compounds Library Max |